A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?
about
Pegylated liposomal doxorubicin in the management of ovarian cancer: a systematic review and metaanalysis of randomized trialsAurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients.Impact of wall shear stress and ligand avidity on binding of anti-CD146-coated nanoparticles to murine tumor endothelium under flow.The Chemoprevention of Ovarian Cancer: the Need and the Options
P2860
A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
A retrospective analysis of pe ...... n cancer: do we still need it?
@ast
A retrospective analysis of pe ...... n cancer: do we still need it?
@en
type
label
A retrospective analysis of pe ...... n cancer: do we still need it?
@ast
A retrospective analysis of pe ...... n cancer: do we still need it?
@en
prefLabel
A retrospective analysis of pe ...... n cancer: do we still need it?
@ast
A retrospective analysis of pe ...... n cancer: do we still need it?
@en
P2093
P2860
P356
P1476
A retrospective analysis of pe ...... n cancer: do we still need it?
@en
P2093
Angela Salvino
Lucia Fiorillo
Nicoletta Staropoli
Pierfrancesco Tassone
Pierosandro Tagliaferri
Simona Gualtieri
P2860
P2888
P356
10.1186/1757-2215-6-10
P577
2013-02-06T00:00:00Z
P5875
P6179
1013053590